Journal of Cardiovascular Translational Research ( IF 2.4 ) Pub Date : 2021-08-31 , DOI: 10.1007/s12265-021-10169-x Soo Ghee Yeoh 1 , Jia Siang Sum 1 , Jing Yi Lai 1 , W Y Haniff W Isa 2 , Theam Soon Lim 1, 3
|
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. CVD includes coronary artery diseases such as angina, myocardial infarction, and stroke. “Lipid hypothesis” which is also known as the cholesterol hypothesis proposes the linkage of plasma cholesterol level with the risk of developing CVD. Conventional management involves the use of statins to reduce the serum cholesterol levels as means for CVD prevention or treatment. The regulation of serum cholesterol levels can potentially be regulated with biological interventions like monoclonal antibodies. Phage display is a powerful tool for the development of therapeutic antibodies with successes over the recent decade. Although mainly for oncology, the application of monoclonal antibodies as immunotherapeutic agents could potentially be expanded to CVD. This review focuses on the concept of phage display for antibody development and discusses the potential target antigens that could potentially be beneficial for serum cholesterol management.
Graphical abstract
中文翻译：
噬菌体展示抗体技术在心血管疾病免疫治疗中的潜力
心血管疾病（CVD）是全球主要的死亡原因之一。心血管疾病包括冠状动脉疾病，例如心绞痛、心肌梗塞和中风。“脂质假说”也称为胆固醇假说，提出血浆胆固醇水平与发生心血管疾病的风险之间存在联系。常规管理包括使用他汀类药物来降低血清胆固醇水平，作为 CVD 预防或治疗的手段。血清胆固醇水平的调节可以通过单克隆抗体等生物干预措施进行调节。噬菌体展示是近十年来成功开发治疗性抗体的有力工具。虽然主要用于肿瘤学，但单克隆抗体作为免疫治疗剂的应用可能会扩展到 CVD。
京公网安备 11010802027423号